Miriam E. Tucker October 06, 2023 HAMBURG, Germany — The “twincretin” tirzepatide (Mounjaro) kept on producing “highly significant weight loss” when the drug was continued in a 1-year follow-up trial, and those who discontinued the drug regained some weight but not all. In Eli Lilly’s SURMOUNT-4 trial of 783 adults with obesity or overweight but not diabetes...
Tag: <span>Tirzepatide</span>
Post
Staggering’ Weight Loss and Benefits in Body Composition With Tirzepatide
Becky Mc Call May 19, 2023 DUBLIN — Substantial reductions in body weight across body mass index (BMI) categories, as well as improved body composition, were achieved with tirzepatide (Mounjaro) in adults for chronic weight management, according to the latest results of the SURMOUNT-1 study. The new analysis showed that up to 63% of participants achieved...
Post
Tirzepatide has unique activity to stimulate insulin secretion, suggests study
by Duke University Medical Center Credit: CC0 Public Domain Tirzepatide, a drug approved for diabetes and on the fast track for approval as a weight loss therapy, works through a unique ability to activate two different mechanisms the body uses to control insulin secretion and energy balance, Duke Health researchers report. The finding reported June 5 in the...
Post
New analysis shows improved body composition with tirzepatide is consistent across adult age groups
by European Association for the Study of Obesity Credit: CC0 Public Domain A new analysis of SURMOUNT-1, the first Phase 3 study of tirzepatide in adults for chronic weight management shows that tirzepatide improves body composition across a range of adult age groups. The analysis is presented by Dr. Louis Aronne, Comprehensive Weight Control Center,...
Post
Eli Lilly plans to make tirzepatide next big thing as pharma experiences ‘unprecedented’ demand for the drug
Paul Schloesser Associate Editor Eli Lilly has been pushing forward on its plans to expand tirzepatide into a megablockbuster, and while the Big Pharma is touting an increase in sales compared to previous quarters, it is trimming down its year-end guidance. The Big Pharma reported $6.94 billion in Q3 revenue, better than expected compared to...
Post
Tirzepatide improves kidney outcomes in T2DM with increased CV risk
An exploratory analysis of data from the SURPASS-4 trial has shown that adults with type 2 diabetes and increased cardiovascular risk receiving tirzepatide experience fewer renal complications, especially new onset of macroalbuminuria; these findings were presented at the annual meeting of the American Diabetes Association, held from June 3 to 7 in New Orleans. Hiddo...
- 1
- 2